Sandbox G: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 2: | Line 2: | ||
{{CMG}}; {{AE}} {{GRN}} | {{CMG}}; {{AE}} {{GRN}} | ||
== | ==Principles of Therapy for ''Clostridium difficile'' infection== | ||
#If a patient has a strong pre-test probability for CDI, empiric therapy should be considered regardless of the laboratory testing result<ref name="pmid23439232">{{cite journal| author=Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH et al.| title=Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. | journal=Am J Gastroenterol | year= 2013 | volume= 108 | issue= 4 |pages= 478-98; quiz 499 | pmid=23439232 | doi=10.1038/ajg.2013.4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23439232 }} </ref>. CDI accounts for about 20% of antibiotic-associated diarrhoea cases in the USA<ref name="Planche2013">{{cite journal|last1=Planche|first1=Tim|title=Clostridium difficile|journal=Medicine|volume=41|issue=11|year=2013|pages=654–657|issn=13573039|doi=10.1016/j.mpmed.2013.08.003}}</ref>.The main risk factors for CDI are: | #If a patient has a strong pre-test probability for CDI, empiric therapy should be considered regardless of the laboratory testing result<ref name="pmid23439232">{{cite journal| author=Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH et al.| title=Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. | journal=Am J Gastroenterol | year= 2013 | volume= 108 | issue= 4 |pages= 478-98; quiz 499 | pmid=23439232 | doi=10.1038/ajg.2013.4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23439232 }} </ref>. CDI accounts for about 20% of antibiotic-associated diarrhoea cases in the USA<ref name="Planche2013">{{cite journal|last1=Planche|first1=Tim|title=Clostridium difficile|journal=Medicine|volume=41|issue=11|year=2013|pages=654–657|issn=13573039|doi=10.1016/j.mpmed.2013.08.003}}</ref>.The main risk factors for CDI are: | ||
##Antibiotic exposure and the first three months after cessation of antibiotics<ref name="pmid22146873">{{cite journal| author=Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ| title=Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. | journal=J Antimicrob Chemother | year= 2012 | volume= 67 | issue= 3 | pages= 742-8 | pmid=22146873 | doi=10.1093/jac/dkr508 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22146873 }} </ref>. Commonly [[clindamycin]], [[penicillins]], [[cephalosporins]], [[fluoroquinolones]],and multiple antibiotics<ref name="KnightSurawicz2013">{{cite journal|last1=Knight|first1=Christopher L.|last2=Surawicz|first2=Christina M.|title=Clostridium difficile Infection|journal=Medical Clinics of North America|volume=97|issue=4|year=2013|pages=523–536|issn=00257125|doi=10.1016/j.mcna.2013.02.003}}</ref>. | ##Antibiotic exposure and the first three months after cessation of antibiotics<ref name="pmid22146873">{{cite journal| author=Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ| title=Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. | journal=J Antimicrob Chemother | year= 2012 | volume= 67 | issue= 3 | pages= 742-8 | pmid=22146873 | doi=10.1093/jac/dkr508 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22146873 }} </ref>. Commonly [[clindamycin]], [[penicillins]], [[cephalosporins]], [[fluoroquinolones]],and multiple antibiotics<ref name="KnightSurawicz2013">{{cite journal|last1=Knight|first1=Christopher L.|last2=Surawicz|first2=Christina M.|title=Clostridium difficile Infection|journal=Medical Clinics of North America|volume=97|issue=4|year=2013|pages=523–536|issn=00257125|doi=10.1016/j.mcna.2013.02.003}}</ref>. |
Revision as of 13:46, 11 June 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Guillermo Rodriguez Nava, M.D. [2]
Principles of Therapy for Clostridium difficile infection
- If a patient has a strong pre-test probability for CDI, empiric therapy should be considered regardless of the laboratory testing result[1]. CDI accounts for about 20% of antibiotic-associated diarrhoea cases in the USA[2].The main risk factors for CDI are:
- Antibiotic exposure and the first three months after cessation of antibiotics[3]. Commonly clindamycin, penicillins, cephalosporins, fluoroquinolones,and multiple antibiotics[4].
- Exposure to Clostridium difficile: up to 25% of hospitalized patients and residents of lonf term facilities are colonized[2].
- Age >65[4].
- History of inflammatory bowel disease[4].
- Any antimicrobial agent should be discontinued[1].
- Current guidelines recommend to choose the treatment regimen based on the severity of the disease[5] [1][2][4]:
- Mild: diarrhea as the only symptom.
- Moderate: raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline.
- Severe: leucocytosis >15,000 cells/mL OR serum creatinene level >1.5 times baseline or abdominal tenderness and serum albumin < 3 g/dL.
- Severe complicated: hypotension or shock, ileus, megacolon, leucocytosis >20,000 cells/mL OR leucopenia <2,000, lactate >2.2 mmol/L, delirium, fever ≥ 38.5 °C, organ failure.
- Duration: recommendations stablish a 10-14 days treatment. If clinical response in 5-7 days, complete 10 days[4].
- Do not use metronidazole beyond the first recurrence episode of CDI or for long-term therapy because of the risk of neurotoxicity[5].
- For mild-to-moderate patients who are intolerant/allergic to metronidazole and for pregnant/breastfeeding women, vancomycin should be used at standard dosing[1].
- The use of anti-peristaltic agents to control diarrhea from confirmed or suspected CDI should be limited or avoided[1].
- Supportive care should be delivered to all patients with severe or severe complicated CDI[1].
- CT scanning of the abdomen and pelvis is recommended in patients with severe complicated CDI[1].
- Surgical consult should be obtained in all patients with complicated CDI[1].
- If there is a third recurrence after a pulsed vancomycin regimen, fecal microbiota transplant should be considered[1].
Medical Therapy
▸ Click on the following categories to expand treatment regimens.[1][5][2][4][6]
Initial episode
▸ Mild to moderate
▸ Severe
▸ Severe complicated
Recurrence
▸ First recurrence
▸ Second recurrence
|
|
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH; et al. (2013). "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections". Am J Gastroenterol. 108 (4): 478–98, quiz 499. doi:10.1038/ajg.2013.4. PMID 23439232.
- ↑ 2.0 2.1 2.2 2.3 Planche, Tim (2013). "Clostridium difficile". Medicine. 41 (11): 654–657. doi:10.1016/j.mpmed.2013.08.003. ISSN 1357-3039.
- ↑ Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ (2012). "Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics". J Antimicrob Chemother. 67 (3): 742–8. doi:10.1093/jac/dkr508. PMID 22146873.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Knight, Christopher L.; Surawicz, Christina M. (2013). "Clostridium difficile Infection". Medical Clinics of North America. 97 (4): 523–536. doi:10.1016/j.mcna.2013.02.003. ISSN 0025-7125.
- ↑ 5.0 5.1 5.2 Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC; et al. (2010). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infect Control Hosp Epidemiol. 31 (5): 431–55. doi:10.1086/651706. PMID 20307191.
- ↑ Kelly CP, LaMont JT (2008). "Clostridium difficile--more difficult than ever". N Engl J Med. 359 (18): 1932–40. doi:10.1056/NEJMra0707500. PMID 18971494.